Plenary Session 4A: Advances in Therapy for Metastatic Non–Small-Cell Lung Cancer (NSCLC)

Conference Correspondent - WCLC 2016 - Lung Cancer


Summaries of the following research efforts will be presented during Plenary Session 4A:

  • Health-Related Quality of Life for Pembrolizumab versus Chemotherapy in Advanced NSCLC with Programmed Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50%: Data from Keynote-024. Brahmer JR, et al.
  • OAK, a Randomized Phase 3 Study of Atezolizumab versus Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses. Gadgeel SM, et al.
  • Durvalumab in Third-Line and Later Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study. Garassino MC, et al.
  • Multicentric French Harmonization Study for PD-L1 Immunohistochemistry (IHC) Testing in NSCLC. Adam J, et al.

Other notable studies of novel immuno-oncology agents and combinations under study for the first-line management of patients with NSCLC include:

  • First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC (CheckMate 012). Nivolumab, a PD-1 immune checkpoint inhibitor, has demonstrated superior efficacy relative to docetaxel in patients with advanced NSCLC who progressed on or after platinum-based chemotherapy regardless of PD-L1 expression. Researchers present findings from a phase 1 study of nivolumab as first-line therapy for advanced NSCLC.
  • Pembrolizumab + Carboplatin and Pemetrexed as First-Line Therapy for Advanced NSCLC (Keynote-021 Cohort G). Pembrolizumab has demonstrated activity in PD-L1–positive advanced NSCLC. Cohort G of the phase 1/2 Keynote-021 study compares pembrolizumab + carboplatin and pemetrexed (CP) with CP in treatment-naive advanced nonsquamous NSCLC.
  • Atezolizumab as First-Line Therapy for Advanced NSCLC in PD-L1–Selected Patients (BIRCH). Atezolizumab, a humanized anti–PD-L1 monoclonal antibody, is being assessed in a phase 2 study in PD-L1–selected advanced NSCLC patients. Initial analysis demonstrated a meaningful objective response rate with durable response in chemotherapy-naive first-line and relapsed PD-L1–selected patients. Researchers reported updated efficacy data in these first-line patients.